Relonchem receives marketing authorization for Moxonidine tablets
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
CRISPR-based detection enables highly specific molecular recognition
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Subscribe To Our Newsletter & Stay Updated